ArticleBlood advances2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
Amir T Fathi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
38 papers cite it
this papercites it